Prospective Clinical Trial of Three Apical Sealing Materials
Prospective Comparative Randomized Clinical Trial of Three Endodontic Retrograde Filling Materials
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients, American Society of Anesthesiologists (ASA) classification I and II
- Any tooth with a single chronic periapical lesion requiring apical microsurgery
- Informed consent signed prior to surgery
Exclusion Criteria:
- Background of drug/alcohol abuse
- Adjacent periapical lesion
- Periodontal disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group 1 EndoSequence
The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
|
The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
Other Names:
|
|
Active Comparator: Group 2 ProRoot MTA
The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
|
The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
Other Names:
|
|
Active Comparator: Group 3 Biodentine
The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
|
The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of remineralization
Time Frame: 6 months
|
The pace at which new bone is redeposited
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-60
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.